Brooks Laboratories: Demerger
Brooks Laboratories is demerging a business into Abridge Speciality Limited.
Board approvalExchange no-objectionNCLT filedMeetingsNCLT orderRecord dateResulting company listed
Next dateNo date has been stated yet.Stage 1 of 7: Board approval
Terms
Each figure links to its source- Entitlement
- 1 share of Abridge Speciality Limited for every 1 share of Brooks Laboratories
- Record date
- Not known: Not yet stated in a filing
- Resulting company lists
- Not known: Not yet stated in a filing
- Resulting company
- Abridge Speciality Limited
Stock exchanges (observation letter): pendingShareholders and creditors: pendingNational Company Law Tribunal: pending
Timeline
12 steps- Board approval14 Oct 2026
- Draft scheme filed with the exchangesDate not yet stated
- Exchange observation letterDate not yet stated
9 more steps, each with its date and filing. Free with a Google sign-in.
Sign in with GoogleSource documents
1 filing1 filing from the exchanges and SEBI, with links. Free with a Google sign-in.
Sign in with GoogleWhat this means for a shareholder
In a demerger a business is moved out of a listed company into a separate company, and the listed company’s shareholders receive shares of it in a stated ratio. The scheme follows the same approvals as a merger: exchanges, shareholders and creditors, and the NCLT.
Shares of the resulting company are credited after the record date and trade only once the exchanges list them, which can take weeks.
Updated 20:44 IST · Information from public filings. Not investment advice.